Dapagliflozin ' s Renal Protection Extends to ' Fast Decline ' of eGFR Dapagliflozin ' s Renal Protection Extends to ' Fast Decline ' of eGFR

Treatment of patients with type 2 diabetes with the SGLT2 inhibitor led to a significant drop in the occurrence of ' fast decline ' of renal function in DECLARE-TIMI 58, the drug ' s main cardiovascular outcome trial.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news